Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  6.00 1.58% 386.00 386.00 396.00 394.00 370.00 380.00 118,043 16:19:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -20.5 -26.2 - 301

Silence Therapeutics Share Discussion Threads

Showing 50901 to 50923 of 50925 messages
Chat Pages: 2037  2036  2035  2034  2033  2032  2031  2030  2029  2028  2027  2026  Older
DateSubjectAuthorDiscuss
12/11/2019
16:25
Shareprice certainly bouncing around a bit. Looking at Euroclear shares on loan data there was a big fall between September and October, so I think some of the spike to £4 may have been driven by short-closing - and perhaps that support has now largely gone, unless others have entered given the rapid rise. ARWR and DRNA have been having a good shareprice run in the last few days so I think perhaps that's lending a bit of support now to offset any profit-taking. Meanwhile I suppose we wait for further news or, optimistically, further buying driven by any perceived valuation mismatch between ARWR/DRNA and SLN.
1gw
08/11/2019
16:16
Mean? What do you mean? What have I said that I should reconsider? I said there was strong resistance at £4...that seems a pretty basic and obvious observation. I guess it makes me a learner amongst all the experts here...
lurker
07/11/2019
18:51
Lurker7 Nov '19 - 11:23 - 48109 of 48112 (Filtered) Being a bit mean there Lurker
luckymouse
07/11/2019
16:50
Nice recovery today. Someone is still accumulating.
stuart14
07/11/2019
11:40
Lurker, Learner, all the same. Not interested.
stuart14
07/11/2019
11:23
Its a very silly precise number with a very silly reason behind it considering the share price has just hit serious resitance at £4...I bought just a few weeks ago and have already sold for a nice profit already...it may not be a round number but at least it is real and in the here and now! I would say some unrealistic expectations here...eps are lower than in 2014 and share price is considerabley higher...
lurker
06/11/2019
14:36
Just so happens it leaves me with a very round number of profit!!
stuart14
06/11/2019
11:30
A very precise number this 8.55?
viku111
06/11/2019
09:44
Here we go- come on £8.55 (I'm gone then!)
stuart14
06/11/2019
08:24
Makes me smile, it's almost like a stubborn stall right now? ?
ukeagle2aus
05/11/2019
10:35
Lurker - Its supposed to respect the fibs whilst on its upward journey
luckymouse
04/11/2019
20:16
It is interesting listening to what SBI say about Quark in their 30th October presentation. It's only a few minutes-worth starting at 23 mins 10 secs, referred to slides 25-27. Talking about DGF, they comment on the increasing amounts of spend incurred through Ph 1, Ph II, Ph III, but then say "once it turns into a drug you're able to possibly generate exploding amounts of profit". They confirm they're expecting a decision from the FDA on transition to the New Drug Application process by December. "If the results are good we would like to decide on a partial or complete sale or an IPO of Quark" and "we are already working with the company to pursue that exit option". They also talk about AKI, which is still in Phase III but say "Phase III is going to end soon" and "we will start to see some insight by the end of the year". So potentially on their way to success in both of the programs using the Silence technology, with a key decision on one in December and potentially some early indications of Phase III results on the other at around the same time. hTtp://www.sbigroup.co.jp/english/investors/disclosure/presentation/
1gw
04/11/2019
17:13
technical analysis suggests that it has hit a short term peak...is that what you mean mr lucky mouse?
lurker
04/11/2019
09:14
Mouse use the ignore button, one question answered by several here who have far more technical knowledge than me is enough. The persistent 'I can't see' is a tell tale sign and I absolutely detest shorting. So jog on and learn somewhere else!
ukeagle2aus
02/11/2019
16:16
Yes - technical analysis, volume analysis, supply analysis, trade target analysis etc Cos you dont understand or accept it, or it doesn't fit your own personal rationale criteria, or you are stress testing for a potential short, your just repeatedly moaning - who wants that kind of 'constructive' input on one of the best bull bases of the yr? It's like getting stuck with the moaner at a party
luckymouse
02/11/2019
00:23
Do you have anything constructive to add ?
learner9
02/11/2019
00:04
then its not for you - bye
luckymouse
01/11/2019
22:54
The more I look at this, the less I understand re the price rise. Silence has yet to demonstrate the technology in the clinic and there has been wholesale change in the management and scientific leaders over the years. The new appointments of chairman and head of R and D don't have any expertise in this field and a key partner (Mallindrocht) is far from successful so far.
learner9
01/11/2019
22:18
Foreign funds are not required to announce their holdings, oddly.
horneblower
01/11/2019
19:56
But of course we don't yet know which fund managers or analysts they might be, as we haven't had any holdings notices since the recent rise started, other than one from Robert Quested relating to an earlier purchase. And there aren't any disclosed shorts.
1gw
01/11/2019
18:49
Yep, all that makes sense. But a big bet on the absence of any new clinical data.
learner9
01/11/2019
18:11
...and the option award which was conditional on achieving a US listing! My 630p target from two weeks ago still applies and £8.75 should follow on after a short consolidation. Good chart, this.
horneblower
01/11/2019
17:39
In terms of what the news is that drove the rise, I personally think it is mainly a delayed reaction to the Mallinckrodt deal. I think that has caused investors (and perhaps shorters) to reassess the company's prospects and take more seriously the proposition that sln could now be on a similar path to Arrowhead. Why it kicked off when it did, I don't know, but perhaps it's as simple as the arrival of competition to buy - 2 buyers competing for shares, both of them convinced that the potential further rise is such that it's worth paying what it takes to build a position (or reduce a short position) as quickly as they can. Yesterday's news on Dicerna, which got a $200m up-front payment (as well as potential milestone payments of $1.47bn) from Roche for an RNAi licensing deal probably added some fuel to yesterday's rise. The next big thing for SLN perhaps is a licensing deal on Lp(a), their "jewel in the crown", and who knows what that might bring in as an up-front payment? But there is also the possibility of Mallinckrodt exercising one or more of its options on further complement targets, or an announcement of an extra-hepatic partnership.
1gw
Chat Pages: 2037  2036  2035  2034  2033  2032  2031  2030  2029  2028  2027  2026  Older
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191113 04:26:25